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Abstract
We wanted to determine whether serial transperineal sector prostate biopsies have a long-term effect on erectile dysfunction (ED). A total 
of 64 men with prostate cancer entered our active surveillance (AS) programme after a transrectal prostate biopsy as well as a confirma-
tory initial transperineal sector prostate biopsy (TPSBx). A repeat TPSBx was performed 24 months later as part of our active surveillance 
protocol. The International Index of Erectile Function-5 (IIEF-5) questionnaire assessed ED at baseline prior to each TPSBx, and at one, 
three, and six months after first and second TPSBx. 
There was a significant short-term deterioration in erectile function on mean IIEF-5 score between baseline (19.5), when compared to one 
month (10.5) (P <0.001) and three months (18.7) (P = 0.001) following first TPSBx. This resolved at six month follow-up (19.6) (P = 0.681). 
Following second TPSBx, there was a deterioration in erectile function between baseline (16.6), compared to one month (7.3), three 
months (13.8), and six months (15.9) (P <0.05) following second TPSBx. Initial TPSBx caused significant short-term ED, which resolved 
by six months. Serial TPSBx appears to have an adverse impact on erectile function in men monitored on AS, increasing the risk of 
long-term ED. This risk should be highlighted and discussed during the consent process.
Keywords: prostatic neoplasms, biopsy, erectile dysfunction, urologic surgical procedures
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Introduction
More men with newly diagnosed prostate cancer are opting to enter AS programmes which allows them to defer or avoid radical therapy if 
their disease is low-risk [1, 2] or until their disease profile changes. This delays the potential complications associated with treatment such 
as erectile dysfunction (ED). Unfortunately, some of these complications can also arise after biopsy. Prostate biopsy is used in AS to initially 
risk stratify men and also to serially detect any increase in volume or grade of disease.
Reports on serial transrectal prostate biopsy (TRBx) disagree on whether serial biopsies affect erectile function in men on AS [3, 4]. 
Transperineal sector prostate biopsy (TPSBx) helps to diagnose a more significant and previously undiagnosed cancer as compared 
to TRBx [5–7], and in many UK centres it is now a routine part of AS. Short-term complications of TPSBx typically include haematuria, 
acute urinary retention, and dysuria [5, 8]. There have been relatively few reports on ED after serial sector biopsies performed via 
the transperineal route [9]. 
As men are likely to have more than one TPSBx during their AS monitoring, it is important to ensure that possible long-term complications 
of AS are accurately identified. We wanted here to determine whether serial TPSBx have a long-term effect on ED.
Materials and methods
The current study consists of a consecutive series of 64 men who underwent TRBx followed by confirmatory TPSBx for entry into our AS 
programme (September 2009 to September 2010). These same men underwent a further staged TPSBx 24 months later, unless if there 
were clinical reasons to perform biopsy earlier such as a rising PSA. As part of our AS programme, these men were monitored with six 
monthly PSA, annual DRE, and a TPSBx every 24 months. TPSBx was performed under general anaesthesia with antibiotic prophylaxis. 
Men were placed in the lithotomy position and the scrotum was displaced upwards to expose the perineum. Transrectal ultrasound and a 
brachytherapy template were used to preferentially target the peripheral zone with core biopsies taken systematically on both sides from 
the anterior, mid, posterior, and basal sectors [5]. Around 24–38 cores were taken depending on prostate volume. A total of 24 cores were 
taken if prostate volume was <30mL, four from the anterior, mid and posterior sectors. If the prostate volume was between 30–50mL, four 
additional cores were taken from the basal sector. Around 38 cores were taken if prostate volume was >50mL, five from the anterior, mid, 
and posterior sectors, and four from the basal sector. A single practitioner performed all biopsies. Pathological characteristics, biopsy time, 
and complication data were collected from medical records. Erectile function was assessed with the International Index of Erectile Func-
tion-5 (IIEF-5) questionnaire prior to each biopsy and then at one, three, and six months following both initial and subsequent TPSBx. The 
degree of ED was stratified into five groups, based on IIEF-5 score [10]. Men were classified with ED if IIEF-5 score was less than 22. Two 
men were excluded from analysis of IIEF-5 as they reported no sexual activity (IIEF-5 = 0).
Paired t-test were performed to evaluate difference in IIEF-5. All statistical analyses were performed using SAS 9.4.
Results
Patients’ demographics and biopsy Gleason scores are summarised in Table 1. Mean age at baseline TPSBx was 64.8 years (±5.9) and 
mean PSA at baseline was 9.2 (±6.3). The majority of men (52%) presented with T2 disease. The most common Gleason score at first 
TPSBx was 3+3 (36%), 3+4 (25%), 4+3/4+5 (9%), and benign (30%). At second TPSBx, Gleason scores were 3+3 (25%), 3+4 (11%), 
4+3/4+4/4+5 (17%), and benign (45%). Table 2 stratifies the degree of ED at baseline and postbiopsy.
With the first TPSBx, there was a statistically significant difference between the IIEF-5 score pre-TPSBx and one month post-TPSBx 
(Table 3, P <0.001). Moreover, there was a statistically significant difference in IIEF-5 score between pre-TPSBx and three months post-
TPSBx (P = 0.001). At six months post-TPSBx, there was no statistically significant difference anymore with the IIEF-5 score pre-TPSBx 
(P = 0.681).
With the second TPSBx, there was a statistically significant difference between the IIEF-5 score pre-TPSBx and at one, three, and six 
months post-TPSBx (Table 3, P <0.05). There was a statistically significant difference in IIEF-5 score difference between the two biopsies, 
at three and six months post-TPSBx (Table 4, P <0.05).
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Table 1. Patient characteristics (N = 64).
 N (%)
Mean Age, years (SD) 63.4 (5.9)
Mean PSA, ng/mL (SD) 9.2 (6.3)
DRE  
T1c 23 (35.9)
T2 33 (51.6)
T3 8 (12.5)
Biopsy 1 Gleason Score
Benign 19 (29.7)
3+3 23 (35.9)
3+4 16 (25.0)
4+3 5 (7.8)
4+5 1 (1.6)
Biopsy 2 Gleason Score
Benign 29 (45.3)
3+3 16 (25.0)
3+4 7 (10.9)
4+3 4 (6.3)
4+4 2 (3.1)
4+5 5 (7.8)
Missing 1 (1.6)
Mean operative time 1, mins (SD) 4.0 (0.9)
Mean operative time 2, mins (SD) 6.0 (1.3)
Table 2. Baseline and postbiopsy International Index Erectile Function-5 Score.
N at pre-TPSBx N at one month post-TPSBx
N at three months 
post-TPSBx
N at six months 
post-TPSBx
First TP
Without ED (IIEF-5 22–25) 29 (45.3%) 0 20 (31.3%) 29 (45.3%)
Mild ED (IIEF-5 17–21) 23 (35.9%) 12 (18.8%) 29 (45.3%) 23 (35.9%)
Mild/Moderate ED (IIEF-5 12–16) 3 (4.7%) 9 (14.1%) 5 (7.8%) 4 (6.3%)
Moderate ED (IIEF-5 8–11) 5 (7.8%) 23 (35.9%) 7 (10.9%) 6 (9.4%)
Severe ED (IIEF-5 1–7) 2 (3.1%) 18 (28.1%) 0 0
No sexual function (IIEF-5 0) 2 (3.1%) 2 (3.1%) 2 (3.1%) 2 (3.1%)
Missing 0 0 1 (1.6%) 0
Second TP
Without ED (IIEF-5 22–25) 13 (20.3%) 3 (4.7%) 5 (7.8%) 12 (18.7%)
Mild ED (IIEF-5 17–21) 27 (42.2%) 5 (7.8%) 25 (39.1%) 24 (37.5%)
Mild/Moderate ED (IIEF-5 12–16) 11 (17.2%) 9 (14.1%) 12 (18.8%) 11 (17.2%)
Moderate ED (IIEF-5 8–11) 5 (7.8%) 7 (10.9%) 4 (6.2%) 8 (12.5%)
Severe ED (IIEF-5 1–7) 3 (4.7%) 25 (39.1%) 4 (6.2%) 1 (1.6%)
No sexual function (IIEF-5 0) 5 (7.8%) 15 (23.4%) 9 (14.1%) 8 (12.5%)
Missing 0 0 5 (7.8%) 0
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Table 3. Baseline mean and difference in International Index Erectile Function-5 Score.
Mean (SD)
Mean difference 
(SD) compared 
with pre-TPSBx - 
P-value
Mean difference 
(SD) compared 
with previous - 
P-value
First TP
pre-TPSBx 19.5 (6.11)
One month post-TPSBx 10.5 (5.4) 9.0 (0.8)
<0.001
9.0 (0.8)
<0.001
Three months post-TPSBx 18.7 (5.6) 0.8 (1.7)
0.001
-8.2 (6.1)
<0.001
Six month post-TPSBx 19.6 (5.4) -0.1 (1.8)
0.681
-0.9 (1.3)
<0.001
Second TP
pre-TPSBx 16.6 (7.1)
One month post-TPSBx 7.3 (6.9) 9.3 (6.6)
<0.001
9.3 (6.6)
<0.001
Three months post-TPSBx 13.8 (7.6) 2.9 (3.9)
<0.001
-6.6 (6.2)
<0.001
Six month post-TPSBx 15.9 (7.7) 0.8 (2.0)
0.003
-2.1 (3.3)
<0.001
Table 4. Difference in International Index Erectile Function-5 Score between two biopsies.
Mean difference 
for first  
TPSBx (SD)
Mean difference
 for second 
TPSBx (SD)
Paired T-test  
P-value
Compared to pre-TPSBx
One month post-TPSBx 9.0 (0.8) 9.3 (6.6) 0.637
Three months post-TPSBx 0.8 (1.7) 2.9 (3.9) <0.001
Six months post-TPSBx -0.1 (1.8) 0.8 (2.0) 0.012
Compared to previous measurement
One month post-TPSBx 9.0 (0.8) 9.3 (6.6) 0.637
Three months post-TPSBx -8.2 (6.1) -6.6 (6.2) 0.046
Six months post-TPSBx -0.9 (1.3) -2.1 (3.3) 0.011
Of those men with normal erectile function before the initial TPSBx (IIEF-5 22-25), three out of 29 (10%) reported significant deterioration 
in their erectile function (IIEF-5 <17) six months post-second TPSBx. 
Complications with TPSBx were rare. There was no clot retention reported after the first TPSBx. Five men (8%) experienced an episode 
of clot retention requiring catheterisation following the second TPSBx, with four of these related to urinary tract infection. There was a 
single episode of acute urinary retention following the first TPSBx, and there were no episodes of sepsis requiring admission with either 
biopsies.
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Discussion
In our cohort of men, there was a significant short-term deterioration in erectile function at one and three months following first TPSBx, com-
pared to pre-TPSBx levels, which resolved at six month follow-up. Following a second biopsy, there was a deterioration in erectile function 
at one, three, and six months post-TPSBx compared to pre-TPSBx levels.
The effect of serial TRBx on erectile function remains unclear. Fujita et al reported on a study with 152 men on AS. There was a significant 
reduction in SHIM (an analogue of the IIEF-5) score with serial TRBx, especially after three biopsies [4]. There was also a significant differ-
ence in men without ED at baseline progressing to ED at follow-up, mean 3.2 (±2.3) years later. Braun et al demonstrated a small reduction 
in IIEF-6 score in a cohort undergoing serial TRBx [3]. They concluded this change was partially attributable to age-related ED, and the 
length of time their men were on AS rather than on serial TRBx. Both studies investigated the association between erectile function and 
biopsy over several years, but did not report on effects in the short and medium-term immediately post-TRBx. Their findings are likely to 
represent multiple variables influencing erectile function, rather than just the effect of a prostate biopsy.
The significant short-term deterioration in erectile function at one and three months following first TPSBx in our study is similar to that previ-
ously reported by Akbal et al, which showed a transient increase in ED at one month post-TPSBx that returned to baseline at six months 
[11]; however this was not seen by Klein et al, who reported no significant difference in IIEF-5 scores at one week, one month, and three 
months post-TPSBx [12]. The mean IIEF-5 score in their cohort was 15.18 which is several points lower than both our group and the Akbal 
et al study, and this in turn may have influenced outcomes.
Pepe et al reported on erectile function in 100 men who underwent repeated TPSBx, and concluded that serial TPSBx did not significantly 
worsen erectile function in the short to medium-term [9]. In contrast, our data suggests that serial TPSBx increases the risk of ED at one, 
three, and six months postbiopsy. Their study failed to report on erectile function before and after initial TPSBx, and also the time difference 
between initial and subsequent TPSBx.
The cause of ED postbiopsy is likely to be multifactorial; a combination of organic aetiology and psychological factors. Serial TPSBx involve 
repeated invasive procedures, and this increases the likelihood of trauma and long-term damage. Zisman et al suggested that biopsy 
related ED may be because of neurovascular bundle damage or secondary trauma because of nerve compression from haematoma or 
oedema [13]. This has been supported by a recent study from Tuncel et al that demonstrated radiological changes in the prostate paren-
chyma and neurovascular bundle in men with ED postbiopsy [14]. In addition, periprostatic nerve block (PPNB) is a commonly used form 
of analgesia for prostate biopsy, and it is likely to be partly responsible for neurovascular bundle damage. PPNB is generally believed to be 
a possible cause of transient ED postbiopsy [15]. 
The psychological impact of requiring a biopsy, anxiety surrounding a prostate cancer diagnosis, waiting for disclosure of results, and 
reduced quality-of-life caused by short-term complications of biopsy are all likely to affect erectile function. Zisman et al reported that 
biopsy-related anxiety peaked just before men were given their results, and the anxiety continued at one month postbiopsy in 64% of con-
firmed prostate cancer diagnosis [13]. Wade et al reported that men who complained of postbiopsy complications such as pain, haematuria, 
and haematospermia as a moderate/major problem had much higher levels of anxiety at one week postbiopsy compared to those who 
reported symptoms as minor/not problematic [16]. At 35 days postbiopsy, this anxiety was noticeably reduced. This decrease in anxiety 
over time may partially explain why IIEF-5 scores in our men recover towards prebiopsy baseline between one and three months follow-up. 
Anxiety and distress are generally not perceived to be associated with management of prostate cancer with AS, [17, 18] and the levels of 
both are generally favourable compared to anxiety and distress linked to radical treatment [19]. 
The Massachusetts Male Ageing Study (MMAS) and the Florey Adelaide Male Ageing Study both highlighted incidence of ED increasing 
with age [20, 21], with the MMAS reporting 26 cases per 1000 men annually in a cohort of men aged 40–69 years, an age range likely to 
mirror a typical AS group. A strength of our study was therefore to limit the effect of age by assessing erectile function immediately before 
and after TPSBx, rather than measuring erectile function at baseline and at a fixed follow-up point. Better data on the incidence of comor-
bidities in our cohort, especially given the strong correlation between LUTS and ED [22] would have helped to distinguish men who may 
have been predisposed to ED because of their pre-existing comorbidities. Our data was collected immediately before and after each TPSBx 
to ensure that any potential ED was likely to be linked solely to the TPSBx, limiting the influence of pre-existing comorbidities.
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Conclusion
Our AS protocol specifies a TPSBx every 24 months. An initial TPSBx can cause significant short-term ED, which generally recovers. Our 
study has shown that there is an increased risk of long-term ED with repeated TPSBx, and this should be considered against disease risk 
when considering further TPSBx. 
The evidence for prostate magnetic resonance imaging (MRI) in selection and monitoring of patients for AS is increasing [23–25], and the 
use of serial imaging, PSA, and DRE to quantify possible disease progression may be helpful in the consideration of further TPSBx. 
This risk of ED should be discussed and highlighted in the consent process.
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